Business
Minovia Therapeutics Announces FDA Fast Track and Rare Pediatric Disease Designations for MNV-201 in Pearson Syndrome
Regulatory Milestone Underscores Urgency and Promise of First-in-Class Mitochondrial Cell Therapy Haifa, ISRAEL, June 30, 2025 (GLOBE NEWSWIRE) -- Minovia
About this update from Launch One Acquisition Corp.
[{"type":"text","content":"Regulatory Milestone Underscores Urgency and Promise of First-in-Class Mitochondrial Cell Therapy\nHaifa, ISRAEL, June 30, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to the Company’s lead investigational compound, MNV-201. The FDA has also granted Rare Pediatric Disease Designation to MNV-201, which is in Phase 2 clinical trials for the treatment of Pearson Syndrome, an ultra-rare and life-threatening mitochondrial disorder affecting children. “Both Fast Track Designation and Pediatric Rare Disease Designation are critical milestones for Minovia, as they strongly validate the clinical approach for our science, while also acknowledging the urgent need for new treatment options for Pearson Syndrome. Importantly, these FDA designations help us to decrease the potential time to market and provide additional benefits across the FDA process that will prove both medically and financially valuable,” said Minovia Co-founder and CEO, Natalie Yivgi-Ohana, Ph.D. FDA’s Fast Track Designation is designed to accelerate the development and review of therapies for serious or life-threatening conditions with unmet medical need. The designation provides Minovia with the opportunity for increased FDA interactions, potential eligibility for priority review, and the opportunity for a rolling submission of a future Biologics License Application (BLA) for MNV-201. Concurrently, Rare Pediatric Disease Designation (RPD) is granted to drugs which are under development for rare childhood diseases and provides the Company with the potential to receive a pediatric priority review voucher (PRV) if the drug is initially approved for that rare childhood disease. A PRV grants the holder an expedited six-month review of a new drug application. PRVs are tradeable and have historically commanded prices in excess of US$100 million, although currently PRV programs are on hold awaiting reauthorization by Congress. Minovia is currently conducting an IND-enabled Phase 2 clinical trial of MNV-201 in Pearson Syndrome. The Company is advancing interactions with the FDA to finalize a pivotal trial design and expects ...